NHS to address workforce shortage by recruiting 2,000 doctors from India

 The healthcare system of United Kingdom is undergoing a major challenge. The main reason is the ongoing deficit in staff in the UK’s healthcare system. The shortage of doctors is mainly because of factors such as low wages, expensive training, and burnout to heavy workload. To get this all of this under control the National Healthcare Service (NHS) has entered into a new workforce agreement with India. 



According to the reports the National Healthcare Service (NHS), is planning to hire doctors from India. It will be on a fast-track basis to alleviate this major issue. They are thinking about hiring about 2,000 doctors. From the news source it is clear that the NHS has set up training centers across major cities in India such as Mumbai, Bangalore, Nagpur, Delhi, Gurugram, Indore, Mysore, Chennai, and Calicut to provide postgraduate training for the first batch of the doctors. This is for the NHS Indian doctor recruitment. National Healthcare Service authorities thinks that, by implementing this in India they will be able to fill the deficit of the staffs.  

It has been stated that after the training period these doctors will soon be deployed to hospital across Britain. The main thing that needs to be noted is that they will also be exempted from the professional and Linguistic Assessments Board (PLAD) examination. This major shift happened because the NHS was facing a shortfall of 49,000 full-time equivalent (FTE) doctors and the medical staff. They were extremely dependent on international recruitment due to chronic staff charges.  

Comments

Post a Comment

Popular posts from this blog

Empowering Pharmacists in Pain Management

Image
  We all know that pain is a universal experience. The management of pain remains a significant challenge worldwide. The ever-growing statistics reveal the importance of pain. There persists concern about inertia in both acknowledging and effectively treating it. According to the Global Pain Index, a comprehensive social study conducted with 19,000 consumers in 2020, a staggering 93% of the world's population experiences pain within a year, with 1 in 3 individuals grappling with it daily.   Introducing the Pain Management Webinar , a comprehensive educational platform meticulously crafted to empower pharmacists and their teams with essential insights and skills to comprehend , handle, and alleviate pain in their patients' daily lives. This complimentary one-hour webinar promises to be a transformative experience, offering invaluable knowledge and practical strategies to enhance patient care and well-being.    As healthcare professionals, pharmacists are supposed to make a me
Read more

Managing incontinence in pharmacy

There are few conditions that bring the degree of isolation, embarrassment and self-consciousness that bowel and urinary incontinence does. In the UK, about 14 million adults experience bladder control problems and 6.5 million have bowel control difficulties. Additionally, there are just under a million children in the UK experiencing continence conditions at any one time. Over £200 million is spent on personal incontinence products; this is in addition to over three times the same amount spent by the NHS. With a rapidly ageing population and unaddressed contributing factors, the significant financial burden, but importantly, the impact on the quality of life and dignity is devastating. We also know that cultural and communication difficulties can create barriers making treatment access and symptom alleviation more difficult. Considering the demography that this has a greater impact on – patients with a learning disability, non-English speakers and disabled patient – it becomes appare
Read more

Aspire expands oncology portfolio with prostate cancer hormone therapy.

Image
Aspire Pharma Limited has reaffirmed its commitment to combating prostate cancer by adding leuprorelin acetate as a branded generic to its oncology portfolio. This move solidifies Aspire's position as a leading specialty generics enterprise.   Leuprorelin acetate is a hormone therapy recommended for patients with high-risk localized, locally advanced, and metastatic prostate cancer . It serves as an alternative to surgical castration for locally advanced cases . A pre-filled syringe containing 11.25mg of leuprorelin acetate (equivalent to 10.72 mg leuprorelin) is injected subcutaneously into the abdomen, providing a vital treatment option for patients .   One of Aspire's primary objectives is to seek "new investment opportunities" that bring products and companies into its portfolio. This aligns closely with Aspire's values and therapeutic focus areas, ensuring a commitment to innovation and patient care. Prostate cancer is the most common cancer among me
Read more